Rituximab and lupus interstitial lung disease: Friend or foe?

International Journal of Rheumatic Diseases

Volumn 14, Issue 1, 2011, Pages

  Efthimiou, Petros ^a,b   Kukar, Manil ^a   Hersh, Alissa ^c,d  

^a LINCOLN MEDICAL AND MENTAL HEALTH CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CARBON MONOXIDE; COMPLEMENT; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; LA ANTIBODY; LEVOFLOXACIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; RO ANTIBODY; STEROID;

ADD ON THERAPY; ADULT; ANTIBIOTIC THERAPY; ANTIBODY TITER; ATELECTASIS; CASE REPORT; CHILL; COMMUNITY ACQUIRED PNEUMONIA; COUGHING; DISEASE EXACERBATION; DRUG MEGADOSE; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; EXERCISE TOLERANCE; FEVER; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART MUSCLE CONTRACTILITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LETTER; LUNG AUSCULTATION; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; LUPUS PNEUMONITIS; MALE; PLEURA EFFUSION; PLEURAL PAIN; PRIORITY JOURNAL; SINUS TACHYCARDIA; SJOEGREN SYNDROME; SPIROMETRY; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; DRUG THERAPY, COMBINATION; DYSPNEA; GLUCOCORTICOIDS; HUMANS; HYDROXYCHLOROQUINE; IMMUNOLOGIC FACTORS; LUNG DISEASES, INTERSTITIAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MYCOPHENOLIC ACID; PREDNISOLONE; RESPIRATORY FUNCTION TESTS; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 79651473080     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2010.01592.x     Document Type: Letter

References (10)

1. Carmier D, Marchand-Adam S, Diot P, Diot E (2008) Respiratory involvement in systemic lupus erythematosus. Rev Mal Respir 25, 1289-303.
2. Pego-Reigosa JM, Medeiros DA, Isenberg DA (2009) Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract Res Clin Rheumatol 23, 469-80.
3. Kupczyk M, Antczak A, Kuna P, Gorski P (2008) Life threatening pneumonia in a lupus patient: a case report. Cases J 1, 70.
4. Smith KG, Jones RB, Burns SM, Jayne DR (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54, 2970-82.
5. Anolik J, Sanz I, Looney RJ (2003) B cell depletion therapy in systemic lupus erythematosus. Curr Rheumatol Rep 5, 350-6.
6. Yoo WH (2010) Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int (forthcoming). DOI .
7. Reynolds JA, Toescu V, Yee CS, Prabu A, Situnayake D, Gordon C (2009) Effects of rituximab on resistant sle disease including lung involvement. Lupus 18, 67-73.
8. Lim SW, Gillis D, Smith W, Hissaria P, Greville H, Peh CA (2006) Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports. Intern Med J 36, 260-2.
9. Kishi J, Nanki T, Watanabe K, Takamura A, Miyasaka N (2009) A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus. Rheumatology (Oxford) 48, 447-8.
10. Bienvenu J, Chvetzoff R, Salles G, et al. (2001) Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2, 378-84.